Malaria Diagnostics Market

Market Definition:

The Malaria Diagnostics Market size was valued at USD 785.04 million in 2021 and is predicted to reach USD 1,197.13 million by 2030 with a CAGR of 4.8% from 2022-2030.

Malaria is an infection caused by parasites, which is highly fatal if it is left untreated. This disease spreads through the bite of infected female Anopheles mosquito that leads to transfer of plasmodium parasites into the human body. These parasites cause malaria symptoms such as fever, chills, and headaches. Diagnosis helps the patient to determine the disease at the right time to avail correct treatment. Diagnosis of malarial infection is done through several procedures and examinations that are conducted in hospitals, clinics, and others diagnostic centres. There are different types of malaria diagnostic tests such as rapid diagnostic test, microscopic diagnostic test and others that are available in the market.

Market Dynamics and Trends:

Increasing prevalence of malaria across the globe is one of the key factors that is creating a positive outlook for the market. Also, the advancements in malaria diagnosis technologies have increased the demand for diagnostic procedures in recent times. Moreover, rising government funding to the healthcare industry, coupled with the increasing investment in R&D, are projected to impact the growth of the malaria diagnostics market positively. For instance, in August 2021, EBioMedicine researchers from the division of infectious diseases developed SHERLOCK assays capable of detecting all Plasmodium species known to cause human malaria and species-specific detection of P. vivax and P. falciparum, the species responsible for the majority of malaria cases worldwide.

However, low awareness among people, especially in under developed countries, regarding malaria diagnostic may restrain the growth of the market to some extent. Also, factors such as stringent regulations, long approval time, and high cost of research & development adversely impacting the global malaria diagnostics market growth. On the other hand, infrastructural development such as hospitals, healthcare centers, and clinics offering malaria diagnosis in low-income countries such as Nigeria, Democratic Republic of Congo, Uganda, and others are expected to offer ample opportunities for the market players.

Market Segmentations and Scope of the Study:

The Malaria Diagnostic market is segmented on the basis of technology, end user and geography. On the basis of technology, the market is divided into clinical diagnostic test, microscopic diagnostic test, rapid diagnostic test (RDT), molecular diagnostic test and other technologies. The molecular diagnostic test is further classified into Conventional PCR and Real-Time PCR (qPCR). On the basis of end user, the market is categorized into hospitals, clinics, blood banks and diagnostic centers. Geographic breakdown and analysis of each of the aforesaid segments includes regions comprising of North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis:

Rest of the world is expected to hold the highest share in the market throughout the forecast period due to rapid surge of malaria cases commonly occurring in this region. Moreover, due to changing climate in the tropical and subtropical region, that causes infectious parasite called Plasmodium falciparum, leads to high malaria transmission. In addition, malaria infection is an endemic is some parts of Africa. According to the WHO, about 95% of the global malaria cases and 96% of global malaria deaths were recorded in African Region in 2020 alone.

However, Asia-Pacific is expected to show a steady rise in the malaria diagnostic market due to the increase in awareness regarding the advantages of early-stage malaria diagnosis for better treatment. Also, high prevalence of malaria burden in countries such as Myanmar, Pakistan, India, and Indonesia contribute to growth in this market in this region.

Competitive Landscape:

The global malaria diagnostic market is comprising of various market players such as Access Bio Inc., Alere Inc., Novartis Diagnostics, Premier Medical Corporation Ltd., Sysmex Corporation, Beckman Coulter, Inc., Abbott Siemens Healthcare, Wako Chemicals, Inc. Olympus Corporation, Novartis AG.

These market players are making collaboration and planning expansion of business across various regions to maintain their dominance in the malaria diagnostic market.

For instance, in December 2020, Access Bio Inc., has collaborated with Intrivo Distributors to commercialize diagnostic testing products that are intended to expand the supply chain for the Carestart line across the U.S. Also, in April 2019, Sysmex acquired CE Certification for Automated Hematology Analyzer, that has automated measurement function contributing to the early detection for red blood cells infected by malaria parasites.

Key Benefits:

• The malaria diagnostic market report provides the quantitative analysis of the current market and estimations through 2022-2030 that assists in identifying the prevailing market opportunities to capitalize on.

• The study comprises a deep dive analysis of the malaria diagnostic market trend including the current and future trends for depicting the prevalent investment pockets in the market.

• The information related to key drivers, restraints and opportunities and their impact on the malaria diagnostic market is provided in the report.

• The competitive analysis of the market players along with their market share in the malaria diagnostic market

• The SWOT analysis and Porters Five Forces model is elaborated in the study.

• Value chain analysis in the market study provides a clear picture of the stakeholders’ roles.

Key Market Segments:

By Technology

• Clinical Diagnostic

• Microscopic Diagnostic

• Rapid Diagnostic Test (RDT)

• Molecular Diagnostic Test

  • Conventional PCR

  • Real-Time PCR (qPCR)

• Other Technologies

By End User

• Hospitals

• Clinics

• Blood Banks

• Diagnostic Centers

By Geography

• North America

  • U.S

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Rest of Europe

• Asia-Pacific

  • China

  • India

  • Japan

  • South Korea

  • Australia

  • Myanmar

  • Indonesia

  • Pakistan

  • Papua New Guinea

  • Cambodia

  • Rest of Asia-Pacific

• RoW

  • Nigeria

  • Democratic Republic of Congo

  • Uganda

  • Saudi Arabia

  • Venezuela

  • Brazil

  • Colombia

  • Remaining Countries

Key Players

• Access Bio Inc.

• Alere Inc.

• Novartis Diagnostics

• Premier Medical Corporation Ltd.

• Sysmex Corporation

• Beckman Coulter, Inc.

• Abbott Siemens Healthcare

• Wako Chemicals Inc.

• Olympus Corporation

• Novartis AG

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Analysis Period	2021–2030
Base Year Considered	2021
Forecast Period	2022–2030
Market Size Estimation	Million (USD)
Market Segmentation	By Technology (Clinical Diagnostics, Microscopic Diagnostic, Rapid Diagnostic Tests (RDTs), Molecular Diagnostic Test and other Technologies), by End user (Hospitals, Clinics, Blood Banks and Diagnostic Centers)
Geographical Segmentation	North America (U.S., Canada, Mexico) Europe (UK, Germany, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, Myanmar, Indonesia, Pakistan, Papua New Guinea, Cambodia, Rest of Asia-Pacific), Rest of the World (Nigeria, Democratic Republic of Congo, Uganda, Saudi Arabia, Venezuela, Brazil, Colombia, Remaining Countries)
Companies Profiled	Access Bio Inc., Alere Inc., Novartis Diagnostics, Premier Medical Corporation Ltd., Sysmex Corporation, Beckman Coulter, Inc., Abbott Siemens Healthcare, Wako Chemicals, Inc. Olympus Corporation, Novartis AG.